Hemagen Diagnostics, Inc. (HMGN)

OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
At close: Feb 25, 2026
19,900%
Market Cap 3.10K
Revenue (ttm) 4.04M
Net Income (ttm) -907.32K
Shares Out 15.50M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 562
Average Volume 9,409
Open 0.0002
Previous Close n/a
Day's Range 0.0002 - 0.0002
52-Week Range 0.0000 - 0.0402
Beta 1,190.55
RSI 48.07
Earnings Date n/a

About Hemagen Diagnostics

Hemagen Diagnostics, Inc. provides human and veterinary diagnostic services worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its proprietary test kits are used to aid in the diagnosis of certain autoimmune and infectious diseases. It also provides human diagnostics, such as universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1985
Employees 15
Stock Exchange OTCMKTS
Ticker Symbol HMGN
Full Company Profile

Financial Performance

In fiscal year 2012, Hemagen Diagnostics's revenue was $4.04 million, a decrease of -21.38% compared to the previous year's $5.14 million. Losses were -$907,315, 3.05% more than in 2011.

Financial Statements

News

There is no news available yet.